Melanoma survivors are at increased risk for second primary keratinocyte carcinoma

Abstract

Background Recent large cohorts have reported that melanoma survivors are at risk of developing second keratinocyte carcinoma (KC). However, the detailed proportion and risk are still unknown. We aimed to comprehensively analyze the risk of developing keratinocyte carcinoma after primary melanoma. Methods We conducted systematic literature research in PubMed, Embase, Web of Science, and Cochrane Library published prior to September 13, 2021. Proportion and standardized incidence ratios (SIR) with its corresponding 95% confidence interval (CI) were pooled for assessing the risk. Results A total of 15 studies encompassing 168,286 patients were included in our analysis. The pooled proportions of melanoma survivors that developed a subsequent basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and KC were 4.11% (95% CI, 1.32–6.90), 2.54% (95% CI, 1.78–3.31), and 5.45% (95% CI, 3.06–7.84), respectively. The risks of developing a second BCC, SCC, and KC in melanoma survivors were 5.3‐fold (SIR 5.30; 95% CI, 4.87–5.77), 2.6‐fold (SIR 2.58; 95% CI, 1.33–5.04), and 6.2‐fold (SIR 6.17; 95% CI, 3.66–10.39) increased in comparison with the general population. Both fixed effects and random effects models were applied in conducting meta‐analysis and reached a consistent conclusion. Conclusions Our results indicated melanoma survivors are at elevated risk of experiencing second primary BCC and SCC, which suggested the significance of surveillance for second primary KC and efforts for prevention in patients with a history of melanoma.

Nanoparticle-Based Treatment Approaches for Skin Cancer: A Systematic Review

“…Per-case treatment costs for basal cell carcinoma and squamous cell carcinomas diagnosed in 2011, secondary to occupational solar radiation exposure, were greater than CAD 5.5 thousand and 10.5 thousand, respectively [ 4 ]. Worse yet, accumulating evidence indicates that primary melanoma survivors are at an elevated risk of developing keratinocyte carcinoma, thereby disproportioning these outcomes across the population [ 5 , 6 ].…”